CDKN2A and acute lymphoblastic leukemia: To evaluate the effects of the ARF peptide on leukaemic cell growth in vivo, we injected 500,000 luciferase-labelled, patient-derived pre-B ALL cells into NSG mice and treated the mice with 10 mg kg−1 ARF peptide on 10 consecutive days intravenously (i.v.)and intraperitoneally (i.p.), respectively, or vehicle control.